MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/14740338.2026.2735075

Медицинская библиотека · Expert opinion on drug safety · 2026

Tolerance of methotrexate co-administered with pegloticase in patients with uncontrolled gout: overview of the findings from the mirror RCT.

Domingues Vinicius, Abdellatif Abdul, Woods Alexis, Yang Quinnie, Weinblatt Michael E, Ji Junzhi, Marder Brad, LaMoreaux Brian

СтатьяПеревод в очереди

Аннотация

BACKGROUND

The efficacy of pegloticase in uncontrolled gout can be limited by antidrug antibody (ADA) formation. Methotrexate (MTX) reduces ADA development, but carries risks, including hepatotoxicity, myelosuppression, and gastrointestinal toxicity. This post hoc analysis of MIRROR evaluated MTX safety in patients with uncontrolled gout receiving pegloticase.

RESEARCH DESIGN AND

METHODS

Patients with uncontrolled gout were randomized 2:1 to receive pegloticase (8-mg infusion every 2 weeks) with blinded MTX (oral 15 mg/week) or placebo (PBO) for 52 weeks. Safety data were collected from patients receiving ≥ 1 dose of blinded MTX or PBO during the run-in period and patients receiving ≥ 1 pegloticase infusion during treatment.

RESULTS

In the safety population (n = 96 for MTX and n = 49 for PBO), treatment-emergent adverse events were similar between groups. Liver enzymes and Fibrosis-4 Index scores, a predictor of hepatic fibrosis progression, were similar at Week 52. Stomatitis was rare (n = 1). Renal function remained stable in both groups. Liver function did not worsen among alcohol users and chronic kidney disease subgroups.

CONCLUSIONS

MTX co-administration with pegloticase did not increase the incidence of liver dysfunction or infection in a post hoc analysis of MIRROR, suggesting that MTX was well tolerated in patients with uncontrolled gout.

CLINICAL TRIAL REGISTRATION: https://clinicaltrials.gov/ identifier is NCT03994731.

Для цитирования: Domingues Vinicius, Abdellatif Abdul, Woods Alexis, Yang Quinnie, Weinblatt Michael E, Ji Junzhi, Marder Brad, LaMoreaux Brian. Tolerance of methotrexate co-administered with pegloticase in patients with uncontrolled gout: overview of the findings from the mirror RCT.. Expert opinion on drug safety. 2026. DOI: 10.1080/14740338.2026.2735075.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.